Skip to main content

ViaNautis Bio Ltd

  • | Biotech or pharma, therapeutic R&D

ViaNautis Bio develops genetic medicines for CNS diseases, including epilepsy, Frontotemporal Dementia (FTD), and Parkinson’s, using proprietary PolyNaut® nanovesicles (PNVs). PNVs enable efficient delivery of DNA, ASO, and mRNA to the brain with high specificity, leveraging ligand-based targeting. We have demonstrated BBB crossing with angiopep2 PNVs, effectively targeting neurons and astrocytes while avoiding microglia. Compared to AAV and LNPs, PNVs offer re-dosing potential, 4°C stability, scalability, and large cargo capacity. ViaNautis is backed by leading investors, including 4BIO, BGF, UCBV, Lilly Ventures, and CFF, and has entered a multi-year, multi-target partnership with Eli Lilly to advance novel genetic medicines.

Address

United Kingdom
Visit website

Contact Exhibitor


Loading
View all Exhibitors
Testimonials

Double Helix


 

Supporting Bank Sponsor


 

Premier Sponsors

Conference Sponsors